MedTrace Logo

Bioequivalence Study of Clonazepam 2 Mg Tablets

NCT06834503 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2025-03-10

No results posted yet for this study

Summary

Demonstrate the bioequivalence in 1 study, in fasting condition of two formulations of clonazepam 2 mg Tablets / tablets immediate release in order to establish that there are no significant pharmacokinetic differences.

Conditions

  • Healthy
  • Healthy Donors

Interventions

DRUG

Rivotril®

Rivotril® 2 mg

DRUG

Clonazepam TQ 2 mg

Test

Sponsors & Collaborators

  • Centro de Atencion e Investigacion Medica

    lead NETWORK

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-06-10
Primary Completion
2025-08-01
Completion
2025-11-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06834503 on ClinicalTrials.gov